大黄虫丸质量标准的提高

目的提高大黄虫丸质量标准。方法通过TLC对大黄虫丸中甘草进行鉴别;采用HPLC法同时测定大黄虫丸中大黄素和大黄酚的含量。结果TLC色谱中均能检出甘草;大黄素在0.0196~0.2352μg范围内呈良好线性关系(r=0.9999);大黄酚在0.0424~1.06μg范围内呈良好线性关系(r=0.9999);平均回收率大黄素为97.5%,RSD=1.48%,大黄酚为101.5%,RSD=1.57%。结论本法准确可靠,简便迅速,可用于大黄虫丸的质量控制。     

大黄虫丸(胶囊)的质量分析

目的评价大黄虫丸(胶囊)的质量现状及存在问题。方法采用法定检验方法检验103批样品,统计分析检验结果 ,对大黄虫丸(胶囊)的质量现状进行评价。结果法定检验显示全检合格率为100%。结论大黄虫丸(胶囊)的质量状况较好,现行标准可行,有的项目可进一步修订提高。     

薄层扫描法测定大黄虫丸中大黄素的含量

应用薄层扫描法测定大黄虫丸中大黄素的含量 ,方法简便 ,其它组分对测定无干扰 ,重现性好 ,可用于该制剂的质量控制     

大黄虫丸治疗乙型肝炎临床疗效观察

大黄虫丸由于具有活血破瘀,通经消痞之功效,用於对乙型肝炎的治疗,临床上收到了良好的效果,使这一流传了近2000年的国药遗产,在新的历史时期发挥出新的贡献。     

高效液相色谱法测定大黄虫丸中黄芩苷的含量

目的建立高效液相色谱法测定大黄(庶虫)虫丸中黄芩苷含量的方法.方法采用LUNA C18(2)色谱柱,乙腈-0.05moL·L-1磷酸二氢钠缓冲液(用磷酸调pH至3.0)=2575,流速为1.0mL·min-1,检测波长为278nm.结果黄芩苷线性范围为526.4～2632.0ng,平均回收率=98.87%,RSD=1.1%.结论该方法简便、可靠、准确,可用于该制剂的质量控制.     

大黄蟅虫丸与拉米夫定联合治疗慢性乙型肝炎活动性肝硬化的临床疗效观察

目的探讨大黄蛀虫丸和拉米夫定治疗慢性乙型肝炎活动性肝硬化的临床疗效。方法随机选择86例活动性肝硬化患者，治疗组46例，大黄蟅虫丸1丸，1日2次，6个月为1疗程；拉米夫定0．1g，1日1次，疗程1年，产生应答者继续服用药物半年。各组在性别、年龄、病程及疾病轻重等方面皆具可比性。观察治疗前后肝功能及1、3、6、12个月的HBV-DNA变化。结果大黄蟅虫丸和拉米夫定治疗组与对照组比较，肝功能、HBV-DNA的阴转率增加，经统计学处理差异有显著性（P〈0．05）。结论大黄蟅虫丸和拉米夫定治疗活动性肝硬化有明显的临床疗效。     

大黄虫胶囊联合陈夏六君子丸治疗脂肪肝肝炎效果观察

目的观察大黄虫胶囊联合陈夏六君子丸对脂肪肝肝炎的治疗效果。方法将入选病例随机分成两组,治疗组36例采用大黄虫胶囊与陈夏六君子丸,对照组18例采用西利宾胺、vitC片和vitBco片,记录两组患者治疗前和3个月后的临床症状变化、肝功能指标、血脂指标和B超检查结果并作检验统计,比较两组是否存在显著性差异。结果两组治疗3个月后,治疗组总有效率为86.1%,对照组为66.6%,两组临床症状改善、肝功能指标、血脂指标和B超检查结果分别经统计学处理有显著性差异(P<0.05)。结论大黄虫胶囊联合陈夏六君子丸治疗脂肪肝肝炎的效果显著,是治疗脂肪肝肝炎的一种较好方法。     

苯磺酸氨氯地平联合复方盐酸阿米洛利或替米沙坦治疗高血压的临床观察

目的:观察苯磺酸氨氯地平联合复方盐酸阿米洛利或替米沙坦治疗高血压的临床疗效和安全性。方法:选择40例高血压患者,随机分为A组(21例)和B组(19例)。A组患者口服苯磺酸氨氯地平2.5～5.0 mg,qd;口服复方盐酸阿米洛利1/2～1片(每片含盐酸阿米洛利2.5 mg、氢氯噻嗪2.5 mg),qd,其中9例患者加服辛伐他汀10 mg,qd。B组患者口服苯磺酸氨氯地平2.5～5.0 mg,qd;口服替米沙坦40～80 mg,qd,其中7例患者加服辛伐他汀10 mg,qd。具体用量根据患者达标水平调节。两组患者疗程均为37～42个月。观察两组患者治疗前、后血压变化及不良反应发生情况。结果:两组患者显效率、有效率及总有效率比较差异均无统计学意义(P>0.05);两组患者治疗后血压达标率较同组治疗前两周显著升高,治疗后平均血压水平较同组治疗前显著降低,差异均有统计学意义(P<0.05),且两组患者治疗后血压达标率比较差异无统计学意义(P>0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05),但A组患者出现1例高尿酸血症、1例低钾血症。结论:苯磺酸氨氯地平联合复方盐酸阿米洛利或替米沙坦均具有显著的降压作用,但苯磺酸氨氯地平联合替米沙坦安全性更高。     

大黄蛰虫丸联合复方甘草酸苷治疗早期肝硬化

早期肝硬化为慢性肝炎发展至一定阶段出现的一种临床常见病症,有一定可逆性,也可经过积极治疗延缓病程进展。所以早期肝硬化的治疗非常关键。我们用大黄蛰虫丸联合复方甘草酸苷治疗早期肝硬化,在改善患者肝功能和降低肝纤维化指标方面效果显著。现报告如下。     

阿德福韦酯联合大黄蛰虫丸治疗早期肝硬化67例

目的观察阿德福韦酯联合大黄蛰虫丸治疗早期乙肝肝硬化的疗效和安全性。方法选择132例曾应用拉米夫定治疗出现YMDD变异HBeAg阴性,HBVDNA阳性的早期乙肝肝硬化患者。随机分为两组：治疗组67例,口服阿德福韦酯10mg/d,连续用药48周,同时口服大黄蛰虫丸6.0/d,分二次,口服4周停4周,共24周。对照组65例,仅给予口服阿德福韦酯10mg/d,连续用药48周。观察肝功能、HBVDNA、白细胞及血小板、脾脏大小及症状的改变。结果两组相比血清氨基转移酶、总胆红素、脾脏回缩程度均明显下降,治疗组更为显著,P〈0.05;白细胞及血小板也均有回升,但治疗组占优势,二组差异有统计学意义,P〈0.05;HBVDNA转阴率,治疗组51例（76.17%）虽高于对照组48例（73.8%）,但差异无统计学意义,P〉0.05;2组中治疗组显效率32例（47.8%）,总有效率91.0%,对照组显效率19例（29.2%）,总有效率64.6%,治疗组均明显优于对照组,差异有统计学意义,P〈0.05。结论阿德福韦酯联合大黄蛰虫丸治疗早期乙肝肝硬化经济又方便,在肝功能、血常规、脾回缩及病毒学方面取得较好的疗效且安全。     

阿德福韦酯联合大黄廑虫丸治疗乙型病毒性肝炎失代偿期肝硬化疗效观察

目的观察阿德福韦酯联合大黄鹰虫丸治疗乙型病毒性肝炎（乙肝）失代偿期肝硬化的疗效。方法将61例乙肝失代偿期肝硬化患者完全随机分为治疗组（31例）和对照组（30例）。2组均采用内科综合性常规治疗,治疗组加用阿德福韦酯和大黄廑虫丸口服,疗程1年。观察并比较2组治疗前后的症状、体征和肝功能、肝纤维化指标变化及乙肝病毒脱氧核糖核酸（HBV-DNA）阴转率。结果治疗组总有效率为93．5％（29／31）,对照组总有效率为80．0％（24／30）,治疗组疗效高于对照组（P〈0．05）。治疗组在治疗后丙氨酸转氨酶（ALT）、总胆红素（TBIL）、血清透明质酸（HA）、血清层黏连蛋白（LN）、Ⅲ型前胶原（PCⅢ）较治疗前明显改善,差异有统计学意义（P〈0．01或P〈0．05）;且ALT、HA、LN、PCⅢ的下降优于对照组,差异有统计学意义（P〈0．01或P〈0．05）。治疗组的HBV—DNA阴转率为87．9％（27／31）,优于对照组的13．5％（4／30）（P〈0．01）。2组治疗均未发现明显药物不良反应。结论阿德福韦酯联合大黄唐虫丸治疗能够通过有效抑制病毒和抗纤维化明显改善乙肝失代偿期肝硬化。     

大黄(蔗虫)虫丸加小金丸治疗乳腺增生病50例

目的 探讨大黄(蔗虫)虫丸加小金丸治疗乳腺增生病的临床疗效.方法 将100例门诊患者随机均分为治疗组(大黄(蔗虫)虫丸加小金丸)和对照组(乳癖消片)各50例,疗程为2个月经周期.结果 治疗组总有效率为98.00%,明显优于对照组的总有效率80.00%,组间比较有非常显著性差异(P<0.01).结论 大黄(蔗虫)虫丸加小金九治疗乳腺增生病临床疗效显著、安全性好.     

阿德福韦酯联合大黄廑虫丸治疗乙型病毒性肝炎失代偿期肝硬化疗效观察

Objective To observe the efficacy of combined adefovir dipivoxil and Rhubarb Zhechong pill for treatment of hepatitis B decompensated cirrhosis. Methods Sixty-one cases of hepatitis B decompensated cir-rhosis patients were randomly divided into two groups. The treatment group was treated with adefovir dipivoxil and rhubarb Zhechong pill, plus conventional medical treatment. All treatments were continued for one year. Symptoms, liver function, hepatic fibrosis changes and the HBV-DNA negative rate before and after treatment were observed. Results The efficiency rate in treatment group was 93.5%, higher than that in control group (80. 0%) (P < O. 05). ALT,TBIL,HA, LN ,PC Ⅲ in treatment group were significantly lower (P < 0.01 or P < 0.05) after them-py. Meanwhile the decrease of ALT, HA, LN, PC Ⅲ after therapy were higher than that in control group (P < 0.01 or P <0.05). The HBV-DNA negative rate in treatment group was 87.9%, higher than that of control group(13.5%) (P < 0. 01). Conclusion Combined Adefovir dipivoxil and rhubarb Zhechong pill can improve the prognosis in hepatitis B decompensated cirrhosis patients.     

阿德福韦酯联合大黄廑虫丸治疗乙型病毒性肝炎失代偿期肝硬化疗效观察

Objective To observe the efficacy of combined adefovir dipivoxil and Rhubarb Zhechong pill for treatment of hepatitis B decompensated cirrhosis. Methods Sixty-one cases of hepatitis B decompensated cir-rhosis patients were randomly divided into two groups. The treatment group was treated with adefovir dipivoxil and rhubarb Zhechong pill, plus conventional medical treatment. All treatments were continued for one year. Symptoms, liver function, hepatic fibrosis changes and the HBV-DNA negative rate before and after treatment were observed. Results The efficiency rate in treatment group was 93.5%, higher than that in control group (80. 0%) (P < O. 05). ALT,TBIL,HA, LN ,PC Ⅲ in treatment group were significantly lower (P < 0.01 or P < 0.05) after them-py. Meanwhile the decrease of ALT, HA, LN, PC Ⅲ after therapy were higher than that in control group (P < 0.01 or P <0.05). The HBV-DNA negative rate in treatment group was 87.9%, higher than that of control group(13.5%) (P < 0. 01). Conclusion Combined Adefovir dipivoxil and rhubarb Zhechong pill can improve the prognosis in hepatitis B decompensated cirrhosis patients.     

阿德福韦酯联合大黄廑虫丸治疗乙型病毒性肝炎失代偿期肝硬化疗效观察

Objective To observe the efficacy of combined adefovir dipivoxil and Rhubarb Zhechong pill for treatment of hepatitis B decompensated cirrhosis. Methods Sixty-one cases of hepatitis B decompensated cir-rhosis patients were randomly divided into two groups. The treatment group was treated with adefovir dipivoxil and rhubarb Zhechong pill, plus conventional medical treatment. All treatments were continued for one year. Symptoms, liver function, hepatic fibrosis changes and the HBV-DNA negative rate before and after treatment were observed. Results The efficiency rate in treatment group was 93.5%, higher than that in control group (80. 0%) (P < O. 05). ALT,TBIL,HA, LN ,PC Ⅲ in treatment group were significantly lower (P < 0.01 or P < 0.05) after them-py. Meanwhile the decrease of ALT, HA, LN, PC Ⅲ after therapy were higher than that in control group (P < 0.01 or P <0.05). The HBV-DNA negative rate in treatment group was 87.9%, higher than that of control group(13.5%) (P < 0. 01). Conclusion Combined Adefovir dipivoxil and rhubarb Zhechong pill can improve the prognosis in hepatitis B decompensated cirrhosis patients.     

阿德福韦酯联合大黄廑虫丸治疗乙型病毒性肝炎失代偿期肝硬化疗效观察

Objective To observe the efficacy of combined adefovir dipivoxil and Rhubarb Zhechong pill for treatment of hepatitis B decompensated cirrhosis. Methods Sixty-one cases of hepatitis B decompensated cir-rhosis patients were randomly divided into two groups. The treatment group was treated with adefovir dipivoxil and rhubarb Zhechong pill, plus conventional medical treatment. All treatments were continued for one year. Symptoms, liver function, hepatic fibrosis changes and the HBV-DNA negative rate before and after treatment were observed. Results The efficiency rate in treatment group was 93.5%, higher than that in control group (80. 0%) (P < O. 05). ALT,TBIL,HA, LN ,PC Ⅲ in treatment group were significantly lower (P < 0.01 or P < 0.05) after them-py. Meanwhile the decrease of ALT, HA, LN, PC Ⅲ after therapy were higher than that in control group (P < 0.01 or P <0.05). The HBV-DNA negative rate in treatment group was 87.9%, higher than that of control group(13.5%) (P < 0. 01). Conclusion Combined Adefovir dipivoxil and rhubarb Zhechong pill can improve the prognosis in hepatitis B decompensated cirrhosis patients.     

大黄蛰虫丸联合拉米夫定治疗乙肝肝硬化临床观察

目的探讨大黄蛰虫丸联合拉米夫定治疗乙肝肝硬化的疗效及临床分析。方法 2010年8月至2011年8月期间,我院诊治的88例乙型病毒性肝炎肝硬化患者,随机将其分为对照组（常规对症治疗）和观察组（对照组基础上,给予大黄蛰虫丸联合拉米夫定治疗）,对两组临床疗效、血清生化指标,以及乙肝病毒脱氧核糖核酸（HBVDNA）阴转率,进行观察和比较。结果与对照组相比,观察组总有效率明显升高,丙氨酸转氨酶ALT和血清透明质酸HA均明显下降,HBVDNA转阴率明显升高,P〈0.05,差异有统计学意义。结论对于乙肝肝硬化患者,大黄蛰虫丸联合拉米夫定治疗疗效显著,明显改善患者的预后质量,值得临床推广。     

大黄(蔗虫)虫丸加小金丸治疗乳腺增生病50例

目的探讨大黄廑虫丸加小金丸治疗乳腺增生病的临床疗效。方法将100例门诊患者随机均分为治疗组（大黄廑虫丸加小金丸）和对照组（乳癖消片）各50例,疗程为2个月经周期。结果治疗组总有效率为98．00％,明显优于对照组的总有效率80．00％,组间比较有非常显著性差异（P〈0．01）。结论大黄廑虫丸加小金丸治疗乳腺增生病临床疗效显著、安全性好。